84年鼠女哪年财运最旺,857comvvv色九欧美激情|85PO_87国产精品欲av国产av资源

[1]王丹輝,賁越,韓梅.林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究[J].中醫(yī)正骨,2014,26(01):27-30.
　Wang Danhui*,Ben Yue,Han Mei..Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(01):27-30.
點擊復(fù)制

林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床研究()
分享到：

《中醫(yī)正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第26卷
期數(shù):
2014年01期
頁碼:
27-30
欄目:
臨床研究
出版日期:
2014-01-28

文章信息/Info

Title:
Clinical study of Rana temporaria oil in the treatment of postmenopausal osteoporosis
作者:
王丹輝1; 賁越2; 韓梅3
1.吉林省中醫(yī)藥科學(xué)院,吉林 長春 130021;
2.吉林省長春市中醫(yī)院,吉林 長春 130021;
3.廣東省廣州市紅十字會醫(yī)院,廣東 廣州 510000
Author(s):
Wang Danhui*; Ben Yue; Han Mei.
*Jilin Academy of Traditional Chinese Medical Sciences,Changchun 130021,Jilin,China
關(guān)鍵詞:
骨質(zhì)疏松; 絕經(jīng)后 林蛙 仙靈骨葆膠囊 治療; 臨床研究性 骨密度 堿性磷酸酶 骨鈣素 雌二醇 白細(xì)胞介素6
Keywords:
Osteoporosis; postmenopausal;  Rana temporaria;  XIANLING GUBAO capsule;  Therapies; investigational;  Bone Density;  Alkaline phosphatase;  Osteocalcin;  Estradiol;  Interleukin-6
摘要:
目的:觀察林蛙油治療絕經(jīng)后骨質(zhì)疏松癥的臨床療效,并探討其作用機制。方法:將60例絕經(jīng)后骨質(zhì)疏松癥患者隨機分為治療組和對照組,每組30例,治療組采用口服林蛙油治療,對照組采用口服仙靈骨葆膠囊治療。治療6個月后,觀察2組患者治療前后臨床癥狀體征評分改變及骨密度、骨代謝指標(biāo)變化情況。結(jié)果:①癥狀體征評分。治療前2組患者癥狀體征評分比較,差異無統(tǒng)計學(xué)意義(t=1.781,P=0.113); 治療6個月后,2組患者癥狀體征評分均較治療前降低[(17.67±3.67)分,(6.44±2.46)分,t=13.808,P=0.000;(20.22±2.17)分,(11.89±1.90)分,t=15.811,P=0.007],治療組降低更明顯 [(11.23±2.44)分,(8.33±1.58)分,t=2.760,P=0.025]。②骨密度。治療前和治療6個月后,2組患者骨密度比較,組間差異均無統(tǒng)計學(xué)意義(t=0.824,P=0.425; t=0.767,P=0.457); 治療6個月后,2組患者骨密度與治療前比較,差異均無統(tǒng)計學(xué)意義[(-2.37±0.84)g·cm-2,(-2.65±0.91)g·cm-2,t=0.811,P=0.432;(-2.19±0.83)g·cm-2,(-2.41±0.56)g·cm-2,t=0.727,P=0.479]。③骨代謝指標(biāo)。治療前2組患者骨堿性磷酸酶、雌二醇、白細(xì)胞介素-6、骨鈣素血清含量比較,組間差異均無統(tǒng)計學(xué)意義(t=1.622,P=0.127; t=1.114,P=0.284; t=1.554,P=0.143; t=1.185,P=0.160)。治療6個月后,2組患者血清骨堿性磷酸酶含量[(17.13±2.13)單位·L-1,(7.80±1.82)單位·L-1,t=12.594,P=0.000;(16.40±1.80)單位·L-1,(10.73±2.12)單位·L-1,t=8.324,P=0.000]、血清白細(xì)胞介素-6含量[(125.20±13.86)μg·L-1,(88.13±10.20)μg·L-1,t=5.795,P=0.000;(131.93±11.07)μg·L-1,(107.40±7.74)μg·L-1,t=9.648,P=0.000]、血清骨鈣素含量[(6.19±0.96)ng·L-1,(3.54±1.12)ng·L-1,t=6.504,P=0.000;(5.80±0.56)ng·L-1,(5.15±0.51)ng·L-1,t=6.733,P=0.000]均較治療前降低,治療組降低更明顯[(9.33±2.87)單位·L-1,(5.67±2.64)單位·L-1,t=7.416,P=0.000;(37.17±19.08)μg·L-1,(24.53±9.85)μg·L-1,t=2.253,P=0.041;(2.65±1.53)ng·L-1,(0.64±0.37)ng·L-1,t=4.820,P=0.000]; 2組患者血清雌二醇含量均較治療前升高[(21.73±5.55)pg·mL-1,(43.40±5.65)pg·mL-1,t=8.208,P=0.000;(24.27±7.72)pg·mL-1,(34.13±5.75)pg·mL-1,t=5.006,P=0.000],治療組升高更明顯[(21.67±10.22)pg·mL-1,(9.87±7.63)pg·mL-1,t=4.209,P=0.001]。結(jié)論:林蛙油在短期內(nèi)未能提高絕經(jīng)后骨質(zhì)疏松癥患者的骨密度,但可以明顯提高其血清雌二醇水平,降低其血清骨堿性磷酸酶、白細(xì)胞介素-6和骨鈣素水平,這可能是林蛙油可以明顯改善PMOP患者的臨床癥狀與體征的作用機制之一。
Abstract:
Objective:To observe the clinical effects of Rana temporaria oil on postmenopausal osteoporosis(PMOP)and to explore its mechanisms of action.Methods:Sixty patients with PMOP were randomly divided into treatment group and control group,30 cases in each group.The patients in treatment group were treated with Rana temporaria oil,while the others in control group were treated with XIANLING GUBAO capsules.The changes in clinical symptoms and signs scores,bone density and bone metabolism index were observed and compared between the 2 groups before and after 6-month treatment.Results:There were no statistical difference in the symptoms and signs scores between the 2 groups before the treatment(t=1.781,P=0.113).while the symptoms and signs scores decreased in both of the 2 groups after 6-month treatment(17.67+/-3.67 vs 6.44+/-2.46 points,t=13.808,P=0.000; 20.22+/-2.17 vs 11.89+/-1.90 points,t=15.811,P=0.007),and the scores decreased more significantly in the treatment group(11.23+/-2.44 vs 8.33+/-1.58 points,t=2.760,P=0.025).There were no statistical difference in bone density between the 2 groups before the treatment and after 6-month treatment(t=0.824,P=0.425; t=0.767,P=0.457).There were no statistical difference in bone density between pre- and post-treatment(-2.37+/-0.84 vs -2.65+/-0.91 g/cm(2),t=0.811,P=0.432; -2.19+/-0.83 vs -2.41+/-0.56 g/cm(2),t=0.727,P=0.479).There were no statistical difference between the 2 groups in the serum concentrations of bone alkaline phosphatase,estradiol,interleukin-6 and osteocalcin before the treatment(t=1.622,P=0.127; t=1.114,P=0.284; t=1.554,P=0.143; t=1.185,P=0.160).The serum concentrations of bone alkaline phosphatase(17.13+/-2.13 vs 7.80+/-1.82 units/L,t=12.594,P=0.000; 16.40+/-1.80 vs 10.73+/-2.12 units/L,t=8.324,P=0.000),interleukin-6(125.20+/-13.86 vs 88.13+/-10.20 μg/L,t=5.795,P=0.000; 131.93+/-11.07 vs 107.40+/-7.74 μg/L,t=9.648,P=0.000)and osteocalcin(6.19+/-0.96 vs 3.54+/-1.12 ng/L,t=6.504,P=0.000; 5.80+/-0.56 vs 5.15+/-0.51 ng/L,t=6.733,P=0.000)decreased in both of the 2 groups after 6-month treatment,and more significant decrease were found in the treatment group(9.33+/-2.87 vs 5.67+/-2.64 units/L,t=7.416,P=0.000; 37.17+/-19.08 vs 24.53+/-9.85 μg/L,t=2.253,P=0.041; 2.65+/-1.53 vs 0.64+/-0.37 ng/L,t=4.820,P=0.000); The serum concentrations of estradiol increased in both of the 2 groups after 6-month treatment(21.73+/-5.55 vs 43.40+/-5.65 pg/mL,t=8.208,P=0.000; 24.27+/-7.72 vs 34.13+/-5.75 pg/mL,t=5.006,P=0.000),and more significant increase were found in the treatment group(21.67+/-10.22 vs 9.87+/-7.63 pg/mL,t=4.209,P=0.001).Conclusion:Although the Rana temporaria oil can not improve bone mineral density in patients with postmenopausal osteoporosis in short period,it can increase the serum estradiol level significantly and decrease the serum concentrations of bone specific alkaline phosphatase,interleukin-6 and osteocalcin,which may be one of the mechanisms of action for Rana temporaria oil to obviously improve clinical symptoms and signs of PMOP patients.

參考文獻/References:

[1] 指導(dǎo)原則編寫委員會.中藥防治骨質(zhì)疏松癥及其骨折的臨床前和臨床評價指導(dǎo)原則[M].北京:人民衛(wèi)生出版社,2006:1.
[2] 徐曉娟,沈霖,楊艷萍,等.青娥丸對絕經(jīng)后骨質(zhì)疏松癥患者骨密度和骨轉(zhuǎn)換標(biāo)志物的影響[J].中國中醫(yī)骨傷科雜志,2013,21(6):8-10.
[3] 劉忠厚,楊定焯,朱漢民,等.中國人骨質(zhì)疏松癥建議診斷標(biāo)準(zhǔn)(第二稿)[J].中國骨質(zhì)疏松雜志,2000,6(1):1-3.
[4] 鄭筱萸.中藥新藥臨床研究指導(dǎo)原則[M].北京:中國醫(yī)藥科技出版社,2002:356-360.
[5] Nelson HD,Walker M,Zakher B,et al.Menopausal hormone therapy for the primary prevention of chronic conditions:a systematic review to update the U.S. Preventive Services Task Force recommendations[J].Ann of Intern Med, 2012,157(2):104-113.
[6] 陳名道,楊穎.絕經(jīng)婦女激素替代治療的困境與中醫(yī)藥治療更年綜合征的前景[J].中西醫(yī)結(jié)合學(xué)報,2003,1(1):9-11.
[7] 王春霖,王麗蘭,姜言功.蛤士蟆油甾體性激素定量分析及藥理作用[J].中藥通報,1985,10(2):44.
[8] 王丹輝,王照輝,吳巍,等.林蛙油含藥血清對成骨細(xì)胞和破骨細(xì)胞增殖和活性的影響[J].中國骨質(zhì)疏松雜志,2010(5):318-321.
[9] Wang DH,Wu W,Tian JM, et al.Effect of oviductus ranae and oviductus ranae eggs on bone metabolism and osteoporosis[J].Chin J of Integr Med,2013,19(7):532-538.
[10] 劉忠厚.骨質(zhì)疏松學(xué)[M ].北京:科學(xué)出版社,1998:217-219.
[11] 勞瑞平,孫桂荷,孫艷紅.補腎健脾活血法對絕經(jīng)后骨質(zhì)疏松癥患者骨堿性磷酸酶的影響[J].光明中醫(yī),2012,27(10):1983-1984.
[12] 張華,陳敢峰,吳俊哲,等.絕經(jīng)后骨質(zhì)疏松癥血清中Leptin、NO、IL-6、BGP及E2的檢測意義[J].中國中醫(yī)骨傷科雜志,2008,16(2):1- 3.
[13] 吳連國,劉康,王定,等.強骨飲治療骨關(guān)節(jié)炎合并骨質(zhì)疏松患者的臨床研究[J].中國中醫(yī)骨傷科雜志,2011,19(12):10-13.

相似文獻/References:

[1]李林軍.應(yīng)用膨脹式椎弓根螺釘內(nèi)固定治療合并骨質(zhì)疏松的 胸腰椎退行性疾病[J].中醫(yī)正骨,2015,27(08):49.
[2]韓艷,溫利平,劉娜,等.補腎活血方對去卵巢大鼠骨代謝及骨密度的影響[J].中醫(yī)正骨,2015,27(12):7.
　HAN Yan,WEN Liping,LIU Na,et al.Effect of Bushen Huoxue Fang(補腎活血方)on bone metabolism and bone mineral density in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(01):7.
[3]李學(xué)朋,朱立國.骨疏康膠囊對去卵巢大鼠骨小梁的影響[J].中醫(yī)正骨,2015,27(12):12.
　LI Xuepeng,ZHU Liguo.Effect of Gushukang Jiaonang(骨疏康膠囊)on bone trabecula in the ovariectomized rats[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(01):12.
[4]陳冠軍,陳揚,莊汝杰.可灌注骨水泥椎弓根螺釘系統(tǒng) 在老年腰椎疾患手術(shù)中的應(yīng)用[J].中醫(yī)正骨,2015,27(02):40.
[5]黃建華,黃建武,李慧輝,等.加味左歸丸對絕經(jīng)后骨質(zhì)疏松癥肝腎不足證 患者骨密度的影響[J].中醫(yī)正骨,2013,25(11):19.
　Huang Jianhua*,Huang Jianwu,Li Huihui,et al.Effect of JIAWEI ZUOGUI pill on bone mineral density in postmenopausal osteoporosis patients with deficiency of liver and kidney[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(01):19.
[6]項旻,楊虹,林愛菊,等.絕經(jīng)后2型糖尿病患者骨質(zhì)疏松與血微量元素的關(guān)系研究[J].中醫(yī)正骨,2013,25(12):20.
　Xiang Min*,Yang Hong,Lin Aiju,et al.Clinical study on the relationship between osteoporosis and serum trace elements levels in postmenopausal women with type 2 diabetes[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2013,25(01):20.
[7]史曉林,李春雯,張志強.弱陽離子磁珠分離技術(shù)和基質(zhì)輔助激光解吸電離飛行時間質(zhì)譜技術(shù)在原發(fā)性Ⅰ型骨質(zhì)疏松癥血清標(biāo)志蛋白篩選中的應(yīng)用[J].中醫(yī)正骨,2014,26(03):5.
　Shi Xiaolin*,Li Chunwen,Zhang Zhiqiang..Application of magnetic beads based weak cation exchange separation technology and matrix-assisted laser desorption-ionization time of flight mass spectrometry technology in screening serum protein markers of primary type-Ⅰ osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(01):5.
[8]李明,徐明雄,馮左基,等.自擬壯骨方治療絕經(jīng)后骨質(zhì)疏松癥的療效及作用機制研究[J].中醫(yī)正骨,2014,26(09):21.
　Li Ming*,Xu Mingxiong,Feng Zuoji,et al.Study on the curative effect and mechanism of action of self-made ZHUANGGU decoction in treatment of postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2014,26(01):21.
[9]陳俊杰,李晴晴,夏瑢.脂代謝及血清內(nèi)脂素水平與絕經(jīng)后骨質(zhì)疏松癥的 相關(guān)性研究[J].中醫(yī)正骨,2012,24(04):16.
　CHEN Jun-jie*,LI Qing-qing,XIA Rong.*.Study on the correlations between the levels of lipid metabolism and serum visfatin and postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(01):16.
[10]許超,肖魯偉,吳承亮.絕經(jīng)后女性骨質(zhì)疏松癥辨證分型與抑郁焦慮的關(guān)系研究[J].中醫(yī)正骨,2011,23(12):3.
　XU Chao*,XIAO Lu-wei,WU Cheng-liang.*.Study on the relationship between the syndrome differ classification and the depression and anxiety for the postmenopausal women with osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(01):3.

更新日期/Last Update: 2014-01-20